风险建模优化降主动脉胸段动脉瘤治疗的患者选择
单中心研究比较2005至2014年438例降主动脉胸段动脉瘤患者(TEVAR 88例,开放手术350例)的早期与长期结局。TEVAR组透析、呼吸衰竭和ICU住院时间更低,早期死亡率在特定高危亚组中更低;倾向评分校正后开放手术、目标人群、糖尿病、外周血管病和急诊状态是早期死亡的预测因素。作者认为在合并显著合并症的老年患者中TEVAR可能更优。
要点
- TEVAR组透析3% vs 开放手术18%(p<0.001),呼吸衰竭10% vs 34%(p<0.001),ICU住院2.0 vs 5.0天(p<0.001)。
- 早期死亡率TEVAR 6% vs 开放手术12%(p=0.121),差异无统计学显著。
- 倾向评分校正后开放手术OR 4.3(p<0.024)与目标人群OR 7.7(p<0.001)为早期死亡预测因素。
核心结论
- 在合并显著合并症的老年患者中,TEVAR较开放手术显示出更优的结果,作者认为在该目标人群中TEVAR可能更可取。
研究设计与样本
- 单中心研究,2005年至2014年共治疗438例降主动脉胸段动脉瘤患者,其中TEVAR 88例、开放手术350例,排除急性夹层与创伤性损伤。
- 回顾围手术期与随访数据,进行分层分析以识别最可能从TEVAR获益的患者,并通过逻辑回归建立TEVAR倾向评分,死亡预测的逻辑回归与Cox回归模型均对倾向评分进行校正。
主要发现
- TEVAR组患者多为老年女性,且急诊状态、慢性阻塞性肺疾病或冠心病更常见。
- TEVAR组与开放手术组的即期运动缺陷(0% vs 1%,p=0.588)、迟发运动缺陷(5% vs 6%,p=1.000)及早期死亡率(6% vs 12%,p=0.121)相似。
- TEVAR组透析(3% vs 18%,p<0.001)、呼吸衰竭(10% vs 34%,p<0.001)及ICU住院时间(2.0 vs 5.0天,p<0.001)均低于开放手术组。
- TEVAR组早期死亡率在七十余岁患者(3% vs 16%,p<0.02)、肾小球滤过率低于60 mL/min者(8% vs 32%,p<0.049)、慢性阻塞性肺疾病者(6% vs 21%,p<0.02)中更低;目标人群定义为归因于TEVAR的死亡率降低四倍(p<0.006)。
- 倾向评分校正后早期死亡预测因素包括开放手术(OR 4.3,p<0.024)、目标人群(OR 7.7,p<0.001)、糖尿病(OR 3,p<0.009)、外周血管病(OR 4.7,p<0.001)及急诊状态(OR 4.6,p<0.001);生存的决定因素为年龄、肾小球滤过率低于60 mL/min、外周血管病、慢性阻塞性肺疾病及急诊状态。
临床怎么用
- 作者认为,在合并显著合并症的老年患者中,TEVAR可能更可取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A single-institutional study comparing early and long-term outcomes of thoracic endovascular aortic repair (TEVAR) and open surgical repair (OSR) was performed to determine the appropriate treatment option for descending thoracic aortic aneurysm (DTAA). METHODS: Between 2005 and 2014, 438 DTAA patients were treated (TEVAR, 88; OSR, 350). Acute dissection and traumatic injury were excluded. Perioperative and follow-up data were reviewed. Stratified analyses were conducted to identify patients most likely to benefit from TEVAR. A propensity score for TEVAR was developed by logistic regression, and predictive logistic and Cox regression models for death were adjusted for propensity score. RESULTS: TEVAR patients were frequently older women with emergent status, chronic obstructive pulmonary disease, or coronary artery disease. TEVAR had similar immediate (0% vs 1%; p = 0.588) and delayed (5% vs 6%, p = 1.000) motor deficits and early mortality (6% vs 12%, p = 0.121) but lower dialysis (3% vs 18%, p < 0.001), respiratory failure (10% vs 34%, p < 0.001), and intensive care unit stay (2.0 vs 5.0 days, p < 0.001). Early mortality after TEVAR was lower in septuagenarians (3% vs 16%, p < 0.02), glomerular filtration rate of less than 60 mL/min (8% vs 32%, p < 0.049), chronic obstructive pulmonary disease (6% vs 21%, p < 0.02), defined as target population that had fourfold mortality reduction (p < 0.006) attributable to TEVAR. Propensity-adjusted predictors of early mortality predictors included OSR (odds ratio [OR], 4.3; p < 0.024), target population (OR, 7.7; p < 0.001), diabetes (OR, 3; p < 0.009), peripheral vascular disease (OR, 4.7; p < 0.001), and emergent status (OR, 4.6; p < 0.001). Propensity-adjusted determinants of survival were age, glomerular filtration rate of less than 60 mL/min, peripheral vascular disease, chronic obstructive pulmonary disease, and emergent status. CONCLUSIONS: In older patients with significant comorbidities, TEVAR demonstrated superior results compared with OSR and may be preferable in this target population.
引用
- Tanaka A, Sandhu HK, Pratt WB, et al. Risk Modeling to Optimize Patient Selection for Management of the Descending Thoracic Aortic Aneurysm. Ann Thorac Surg. 2017. PMID: 29275829. doi:10.1016/j.athoracsur.2017.09.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。